Physician profile
Ashley Ko
NPI 1821462045
$4,170.12
in general payments reported to CMS, 2019-2025
27 companies · $2,802 in 2025
The $2,802 reported for 2025 was more than what 98% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $22.72 · 2024: $1,345 · 2025: $2,802.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,112 · Education: $58.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,111.87 |
| Education | $58.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $420.25 | 2024-2025 | Voquezna |
| Amgen INC. | $389.59 | 2024-2025 | Evenity, Repatha, Otezla |
| Madrigal Pharmaceuticals | $336.62 | 2024-2025 | Rezdiffra, Resmetirom |
| Cequr Corporation | $328.22 | 2024-2025 | Cequr Simplicity |
| Acadia Pharmaceuticals INC | $317.80 | 2023-2024 | Nuplazid |
| Lilly USA, LLC | $238.75 | 2024-2025 | Kisunla, Zepbound, Mounjaro |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $212.60 | 2024-2025 | Caplyta |
| Corcept Therapeutics | $196.46 | 2025 | Korlym |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $189.68 | 2025 | Rexulti |
| Alnylam Pharmaceuticals INC. | $168.27 | 2025 | Amvuttra |
| Lundbeck LLC | $163.88 | 2024-2025 | Rexulti |
| Viatris Specialty LLC | $160.31 | 2025 | Yupelri |
| Otsuka America Pharmaceutical, INC. | $156.93 | 2024-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $139.64 | 2025 | Spravato |
| Agios Pharmaceuticals, INC. | $126.30 | 2025 | Pyrukynd |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $119.74 | 2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $103.47 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $96.42 | 2024 | Dojolvi |
| Alkermes, INC. | $89.65 | 2024 | Vivitrol |
| Verona Pharma, INC. | $52.50 | 2025 | Ohtuvayre |
| Neurocrine Biosciences, INC. | $38.08 | 2024 | Ingrezza |
| Exact Sciences Corporation | $27.24 | 2025 | The Cologuard Plus Collection Kit |
| Sumitomo Pharma America, INC. | $22.20 | 2025 | Gemtesa |
| Novo Nordisk INC | $22.08 | 2025 | Rybelsus, Ozempic |
| Sanofi-Aventis U.S. LLC | $20.88 | 2025 | |
| Dexcom, INC. | $17.48 | 2025 | Dexcom G6 Transmitter |
| Echosens North America, INC. | $15.08 | 2024 | Fibroscan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Ko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.